This resource center provides physicians and healthcare professionals with a clinical overview of TDT's technology, compares it to current testing models, and provides a guide for ordering tests for patients.

Tests developed by TDT for colorectal cancer staging and post-treatment monitoring for recurrence represent significant improvements compared to staging by histopathology and post-treatment monitoring using CEA.

TDT tests are being introduced under on-site testing guidelines established by federal CLIA '88 statutes.

Included in this section are: